Takezaki T, Nakazaki K, Toyama K, et al. - Given bendamusutine plus rituximab (BR) regimen represents one of the standard treatment regimens for indolent B‐cell lymphomas, still the likelihood of decrease of cycles of BR therapy without compromising therapeutic impacts is not still unveiled, thus, researchers analyzed 57 cases retrospectively, including 40 follicular lymphoma cases who received BR regimen in their institute. The overall response rate was 86.0% and complete response rate was 54.4%. Patients were then split according to the number of received cycles of BR regimen. Longer progression‐free survival was seen in 21 (36.8%) cases receiving just 4 cycles vs that of 20 cases who were administered five or 6 cycles. Based on the findings of this study, patients should be given four cycles at least if possible, and no inferior outcome was exhibited by patients who discontinued BR after four cycles when compared with those who received five or six cycles. Overall, cessation after four cycles may be allowed in some patients exhibiting complete response to BR regimen.